Pharmacokinetic/Pharmacodynamic (PK/PD) modeling of antipyretic effect of meloxicam: A preferential cyclooxygenase inhibitor in rat

(inhibitory E max model), estimated K IN (1.43, 0.63, 0.51, and 0.42 1/h), K out (0.005, 0.008, 0.015, and 0.028 1/h), and K syn (0.29, 0.42, 0.076, and 0.03 h); estimates for IC 50 (concentration of meloxicam in plasma eliciting half of maximum inhibition of IR(t) or K IN ) were 146.19, 379.51, 645.05, and 676.44 ng/ml of 1, 3, 7 and 10 mg/kg dose received by groups, respectively. This model appropriately describes the time course of pharmacological response to meloxicam to various doses, in terms of its mechanism of action and pharmacokinetics.